Lyra Therapeutics, Inc. announced a 1-for-50 reverse stock split effective May 27, 2025, with shares trading on a split-adjusted basis starting May 28, 2025; stockholders will receive cash for any fractional shares. Additionally, data from the ENLIGHTEN 2 Phase 3 Trial, showing positive outcomes for LYR-210, was disclosed on June 2, 2025.